Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Food therapy of scutellarein ameliorates pirarubicin‑induced cardiotoxicity in rats by inhibiting apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Athens, Greece : D. A. Spandidos
    • الموضوع:
    • نبذة مختصرة :
      Pirarubicin (THP) is one of the most commonly used antineoplastic drugs in clinical practice. However, its clinical application is limited due to its toxic and heart‑related side effects. It has been reported that oxidative stress, inflammation and apoptosis are closely associated with cardiotoxicity caused by pirarubicin (CTP). Additionally, it has also been reported that scutellarein (Sc) exerts anti‑inflammatory, antioxidant, cardio‑cerebral vascular protective and anti‑apoptotic properties. Therefore, the present study aimed to investigate the effect of food therapy with Sc on CTP and its underlying molecular mechanism using echocardiography, immunofluorescence, western blot, ROS staining, and TUNEL staining. The in vivo results demonstrated that THP was associated with cardiotoxicity. Additionally, abnormal changes in the expression of indicators associated with oxidative stress, ferroptosis and apoptosis were observed, which were restored by Sc. Therefore, it was hypothesized that CTP could be associated with oxidative stress, ferroptosis and apoptosis. Furthermore, the in vitro experiments showed that Sc and the NADPH oxidase 2 (NOX2) inhibitor, GSK2795039 (GSK), upregulated glutathione peroxidase 4 (GPX4) and inhibited THP‑induced oxidative stress, apoptosis and ferroptosis. However, cell treatment with the ferroptosis inhibitor, ferrostatin‑1, or inducer, erastin, could not significantly reduce or promote, respectively, the expression of NOX2. However, GSK significantly affected ferroptosis and GPX4 expression. Overall, the results of the present study indicated that food therapy with Sc ameliorated CTP via inhibition of apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress, thus suggesting that Sc may be a potential therapeutic drug against CTP.
    • References:
      Redox Biol. 2021 May;41:101947. (PMID: 33774476)
      Lancet. 2023 Apr 15;401(10384):1243-1245. (PMID: 37061256)
      Oxid Med Cell Longev. 2016;2016:4350965. (PMID: 26998193)
      Antioxidants (Basel). 2020 Feb 16;9(2):. (PMID: 32079097)
      Nat Commun. 2020 Jan 23;11(1):433. (PMID: 31974380)
      J Cell Mol Med. 2020 Feb;24(3):2260-2271. (PMID: 31957170)
      Circ Res. 2014 Jan 31;114(3):524-37. (PMID: 24481843)
      Front Pharmacol. 2022 Aug 19;13:924826. (PMID: 36059982)
      Oxid Med Cell Longev. 2020 Jul 19;2020:2930463. (PMID: 32774667)
      Front Pharmacol. 2022 Mar 16;13:841410. (PMID: 35370724)
      Redox Biol. 2020 Jan;28:101328. (PMID: 31574461)
      Protein Cell. 2023 Mar 16;14(2):84-86. (PMID: 36929006)
      Front Pharmacol. 2021 Oct 15;12:733805. (PMID: 34721023)
      Biomed Pharmacother. 2019 Sep;117:109042. (PMID: 31228804)
      Nat Chem Biol. 2019 Dec;15(12):1137-1147. (PMID: 31740834)
      Circ Res. 2020 Jul 31;127(4):e108-e125. (PMID: 32392088)
      Science. 2011 Sep 9;333(6048):1440-5. (PMID: 21903813)
      Trends Endocrinol Metab. 2014 Sep;25(9):452-63. (PMID: 25066192)
      Int J Biol Sci. 2022 Jan 1;18(2):760-770. (PMID: 35002523)
      Redox Biol. 2021 Oct;46:102089. (PMID: 34364220)
      Life Sci. 2018 May 1;200:26-30. (PMID: 29534993)
      Lancet. 2015 May 9;385(9980):1812-4. (PMID: 25740287)
      Obes Res Clin Pract. 2020 Jul - Aug;14(4):368-374. (PMID: 32631803)
      Eur J Heart Fail. 2014 Apr;16(4):358-66. (PMID: 24464789)
      J Diabetes Res. 2018 Mar 18;2018:6823058. (PMID: 29744367)
      J Clin Oncol. 2008 Aug 1;26(22):3777-84. (PMID: 18669466)
      Cardiovasc Res. 2010 Oct 1;88(1):40-50. (PMID: 20668004)
      Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282. (PMID: 33495651)
      Cell Res. 2022 Jul;32(7):687-690. (PMID: 35352032)
      Front Cardiovasc Med. 2021 Jul 14;8:685434. (PMID: 34336950)
      Physiol Rev. 2007 Jan;87(1):245-313. (PMID: 17237347)
      Cell Res. 2021 Feb;31(2):107-125. (PMID: 33268902)
      Nature. 2019 Nov;575(7784):597-598. (PMID: 31768036)
      Nat Rev Drug Discov. 2020 Dec;19(12):825-826. (PMID: 33173229)
      Oxid Med Cell Longev. 2022 Sep 6;2022:9966750. (PMID: 36111166)
      Biosci Trends. 2012 Feb;6(1):19-25. (PMID: 22426099)
      Antioxidants (Basel). 2022 Jan 25;11(2):. (PMID: 35204107)
      Biochem Pharmacol. 2019 Jan;159:82-95. (PMID: 30447218)
      Nat Rev Mol Cell Biol. 2007 Oct;8(10):813-24. (PMID: 17848967)
      Br J Pharmacol. 2017 Nov;174(21):3677-3695. (PMID: 28261787)
      Redox Biol. 2018 Jun;16:189-198. (PMID: 29524841)
      Annu Rev Pharmacol Toxicol. 2007;47:143-83. (PMID: 17029566)
      Nature. 2019 Nov;575(7784):688-692. (PMID: 31634900)
      ACS Cent Sci. 2017 Mar 22;3(3):232-243. (PMID: 28386601)
      Drug Resist Updat. 2016 Nov;29:90-106. (PMID: 27912846)
      Phytomedicine. 2018 Feb 1;40:125-139. (PMID: 29496165)
      Nat Rev Cardiol. 2022 Sep;19(9):574. (PMID: 35869158)
      Nat Rev Drug Discov. 2010 Apr;9(4):253-4. (PMID: 20369394)
      Cardiovasc Res. 2010 Oct 1;88(1):5-6. (PMID: 20685941)
      Cell. 2012 May 25;149(5):1060-72. (PMID: 22632970)
      Cell. 2022 Jul 7;185(14):2401-2421. (PMID: 35803244)
      Cell Death Dis. 2023 Feb 2;14(2):78. (PMID: 36732325)
    • Contributed Indexing:
      Keywords: apoptosis; cardiotoxicity; ferroptosis; oxidative stress; pirarubicin; scutellarein
    • الرقم المعرف:
      0 (Aminopyridines)
      7V515PI7F6 (Apigenin)
      80168379AG (Doxorubicin)
      0 (GSK2795039)
      EC 1.6.3.- (NADPH Oxidase 2)
      D58G680W0G (pirarubicin)
      P460GTI853 (scutellarein)
      0 (Sulfonamides)
    • الموضوع:
      Date Created: 20240322 Date Completed: 20240325 Latest Revision: 20240404
    • الموضوع:
      20240404
    • الرقم المعرف:
      PMC10979251
    • الرقم المعرف:
      10.3892/mmr.2024.13208
    • الرقم المعرف:
      38516760